Targeted therapies and immunotherapy are redefining transplantation in AML

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses how targeted therapies and immunotherapies are reshaping the role of allogeneic stem cell transplantation in acute myeloid leukemia (AML). Prof. Nagler highlights the continued curative role of transplantation in myeloid malignancies and explains how newer therapies are increasingly being integrated before and after transplant to improve outcomes. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.